Alnylam Pharmaceuticals
ALNY
#644
Rank
HK$245.15 B
Marketcap
HK$1,894
Share price
-1.30%
Change (1 day)
61.23%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -HK$32.20

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -HK$31.96. In 2022 the company made an earnings per share (EPS) of -HK$72.24 a decrease over its 2021 EPS that were of -HK$55.99.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-HK$32.20-55.43%
2022-HK$72.2429.03%
2021-HK$55.99-3.36%
2020-HK$57.93-8.48%
2019-HK$63.307.67%
2018-HK$58.7939.74%
2017-HK$42.0712.94%
2016-HK$37.2538.84%
2015-HK$26.83-32.88%
2014-HK$39.97259.44%
2013-HK$11.12-31.25%
2012-HK$16.1752.94%
2011-HK$10.5830.77%
2010-HK$8.09-8.77%
2009-HK$8.8678.13%
2008-HK$4.98-70.78%
2007-HK$17.0399.09%
2006-HK$8.55-43.88%
2005-HK$15.24-82.33%
2004-HK$86.26-59.23%
2003-HK$211.59

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-HK$13.22-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$290.52-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$60.89 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$2.10-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$13.14-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$29.08-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
HK$24.73-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-HK$15.55-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel